Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy
- PMID: 27209498
- DOI: 10.1016/j.ijrobp.2016.01.065
Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy
Abstract
Purpose: To identify the optimal dose parameters predictive for local/lobar control after stereotactic ablative radiation therapy (SABR) in early-stage non-small cell lung cancer (NSCLC).
Methods and materials: This study encompassed a total of 1092 patients (1200 lesions) with NSCLC of clinical stage T1-T2 N0M0 who were treated with SABR of 50 Gy in 4 fractions or 70 Gy in 10 fractions, depending on tumor location/size, using computed tomography-based heterogeneity corrections and a convolution superposition calculation algorithm. Patients were monitored by chest CT or positron emission tomography/CT and/or biopsy after SABR. Factors predicting local/lobar recurrence (LR) were determined by competing risk multivariate analysis. Continuous variables were divided into 2 subgroups at cutoff values identified by receiver operating characteristic curves.
Results: At a median follow-up time of 31.7 months (interquartile range, 14.8-51.3 months), the 5-year time to local recurrence within the same lobe and overall survival rates were 93.8% and 44.8%, respectively. Total cumulative number of patients experiencing LR was 40 (3.7%), occurring at a median time of 14.4 months (range, 4.8-46 months). Using multivariate competing risk analysis, independent predictive factors for LR after SABR were minimum biologically effective dose (BED10) to 95% of planning target volume (PTVD95 BED10) ≤86 Gy (corresponding to PTV D95 physics dose of 42 Gy in 4 fractions or 55 Gy in 10 fractions) and gross tumor volume ≥8.3 cm(3). The PTVmean BED10 was highly correlated with PTVD95 BED10. In univariate analysis, a cutoff of 130 Gy for PTVmean BED10 (corresponding to PTVmean physics dose of 55 Gy in 4 fractions or 75 Gy in 10 fractions) was also significantly associated with LR.
Conclusions: In addition to gross tumor volume, higher radiation dose delivered to the PTV predicts for better local/lobar control. We recommend that both PTVD95 BED10 >86 Gy and PTVmean BED10 >130 Gy should be considered for SABR plan optimization.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance.Radiother Oncol. 2014 Mar;110(3):499-504. doi: 10.1016/j.radonc.2014.02.002. Epub 2014 Mar 11. Radiother Oncol. 2014. PMID: 24630539
-
The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1011-1020. doi: 10.1016/j.ijrobp.2016.08.033. Epub 2016 Aug 31. Int J Radiat Oncol Biol Phys. 2016. PMID: 27869080
-
A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.J Thorac Oncol. 2012 Sep;7(9):1382-93. doi: 10.1097/JTO.0b013e318260e00d. J Thorac Oncol. 2012. PMID: 22843086
-
Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):160-171. doi: 10.1016/j.ijrobp.2019.03.045. Epub 2019 Apr 5. Int J Radiat Oncol Biol Phys. 2021. PMID: 30954520 Free PMC article. Review.
-
Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non-Small-Cell Lung Cancer: CEPO Review and Recommendations.J Thorac Oncol. 2015 Jun;10(6):872-82. doi: 10.1097/JTO.0000000000000524. J Thorac Oncol. 2015. PMID: 26001140 Review.
Cited by
-
CyberKnife® stereotactic radiation therapy for stage I lung cancer and pulmonary oligometastases: is fiducial implantation still relevant?-a cohort study.J Thorac Dis. 2023 Sep 28;15(9):4636-4647. doi: 10.21037/jtd-22-1245. Epub 2023 Aug 11. J Thorac Dis. 2023. PMID: 37868838 Free PMC article.
-
Dose-effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients.Radiat Oncol. 2022 Dec 23;17(1):211. doi: 10.1186/s13014-022-02183-3. Radiat Oncol. 2022. PMID: 36564845 Free PMC article.
-
The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study.Front Oncol. 2022 Oct 14;12:921473. doi: 10.3389/fonc.2022.921473. eCollection 2022. Front Oncol. 2022. PMID: 36313653 Free PMC article.
-
Development of a quantitative analysis method for assessing patient body surface deformation using an optical surface tracking system.Radiol Phys Technol. 2022 Dec;15(4):367-378. doi: 10.1007/s12194-022-00676-0. Epub 2022 Aug 30. Radiol Phys Technol. 2022. PMID: 36040622
-
Relationship between Dose Prescription Methods and Local Control Rate in Stereotactic Body Radiotherapy for Early Stage Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis.Cancers (Basel). 2022 Aug 5;14(15):3815. doi: 10.3390/cancers14153815. Cancers (Basel). 2022. PMID: 35954478 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
